(Q38172451)

30 August 2017

title

Adoptive T-cell therapy for hematological malignancies using T cells gene-modified to express tumor antigen-specific receptors (English)

1 reference

30 August 2017

Hiroshi Fujiwara

1

1 reference

30 August 2017

publication date

19 December 2013

1 reference

International Journal of Hematology

30 August 2017

published in

1 reference

30 August 2017

volume

99

1 reference

30 August 2017

issue

2

1 reference

30 August 2017

page(s)

123-131

1 reference

https://scigraph.springernature.com/pub.10.1007/s12185-013-1493-7

30 August 2017

exact match

0 references

cites work

Graft-versus-leukemia reactions in allogeneic chimeras

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Therapy of relapsed leukemia after allogeneic hematopoietic cell transplantation with T cells specific for minor histocompatibility antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Next-generation leukemia immunotherapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Generation of multi-leukemia antigen-specific T cells to enhance the graft-versus-leukemia effect after allogeneic stem cell transplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Adoptive cell therapy for the treatment of patients with metastatic melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Adoptive immunotherapy with unselected or EBV-specific T cells for biopsy-proven EBV+ lymphomas after allogeneic hematopoietic cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Cytotoxic T lymphocytes for the treatment of viral infections and posttransplant lymphoproliferative disorders in transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Requisite considerations for successful adoptive immunotherapy with engineered T-lymphocytes using tumor antigen-specific T-cell receptor gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Minimally cultured or selected autologous tumor-infiltrating lymphocytes after a lympho-depleting chemotherapy regimen in metastatic melanoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Treating cancer with genetically engineered T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Directed evolution of human T-cell receptors with picomolar affinities by phage display.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Immunotherapy with CTLs restricted by nonself MHC.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Circumventing tolerance to a human MDM2-derived tumor antigen by TCR gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Enhanced antitumor activity of T cells engineered to express T-cell receptors with a second disulfide bond.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Targeting the Wilms tumor antigen 1 by TCR gene transfer: TCR variants improve tetramer binding but not the function of gene modified human T cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Lethal graft-versus-host disease in mouse models of T cell receptor gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Improved expression and reactivity of transduced tumor-specific TCRs in human lymphocytes by specific silencing of endogenous TCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

A Promising Vector for TCR Gene Therapy: Differential Effect of siRNA, 2A Peptide, and Disulfide Bond on the Introduced TCR Expression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Editing T cell specificity towards leukemia by zinc finger nucleases and lentiviral gene transfer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

A foundation for universal T-cell based immunotherapy: T cells engineered to express a CD19-specific chimeric-antigen-receptor and eliminate expression of endogenous TCR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Novel adoptive T-cell immunotherapy using a WT1-specific TCR vector encoding silencers for endogenous TCRs shows marked antileukemia reactivity and safety

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

The basic principles of chimeric antigen receptor design

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Control of large, established tumor xenografts with genetically retargeted human T cells containing CD28 and CD137 domains.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Costimulation by chimeric antigen receptors revisited the T cell antitumor response benefits from combined CD28-OX40 signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

CAR-T cells and solid tumors: tuning T cells to challenge an inveterate foe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

How do CARs work?: Early insights from recent clinical studies targeting CD19.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

T cell activation by antibody-like immunoreceptors: increase in affinity of the single-chain fragment domain above threshold does not increase T cell activation against antigen-positive target cells but decreases selectivity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Cancer regression in patients after transfer of genetically engineered lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Enhanced-affinity murine T-cell receptors for tumor/self-antigens can be safe in gene therapy despite surpassing the threshold for thymic selection

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

T cells expressing chimeric antigen receptors can cause anaphylaxis in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

The role of hypercytokinemia in the pathophysiology of tumor lysis syndrome (TLS) and the treatment with continuous hemodiafiltration using a polymethylmethacrylate membrane hemofilter (PMMA-CHDF).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I-II study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Inducible apoptosis as a safety switch for adoptive cell therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Can immunotherapy specifically target acute myeloid leukemic stem cells?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Biological therapy and the immune system in patients with chronic myeloid leukemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Adoptively transferred effector cells derived from naive rather than central memory CD8+ T cells mediate superior antitumor immunity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Expression profiling of TCR-engineered T cells demonstrates overexpression of multiple inhibitory receptors in persisting lymphocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Rejection of Syngeneic Colon Carcinoma by CTLs Expressing Single-Chain Antibody Receptors Codelivering CD28 Costimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS12185-013-1493-7

Chimeric receptors providing both primary and costimulatory signaling in T cells from a single gene product

21 January 2018

1 reference

12 December 2020

Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation

1 reference

12 December 2020

NCI First International Workshop on The Biology, Prevention, and Treatment of Relapse After Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on the Biology Underlying Recurrence of Malignant Disease following Allogeneic

1 reference

12 December 2020

Serial triggering of TCRs: a basis for the sensitivity and specificity of antigen recognition

1 reference

12 December 2020

Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule

1 reference

12 December 2020

Graft-versus-host disease

1 reference

12 December 2020

10.1007/S12185-013-1493-7

Identifiers

DOI

1 reference

Dimensions Publication ID

30 August 2017

1038039831

0 references

1 reference